Related Experiment Video

Updated: Jul 10, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Structure-based optimization of PKCtheta inhibitors

L Mosyak1, Z Xu, D Joseph-McCarthy

  • 1Chemical and Screening Sciences, Wyeth Research, Cambridge, MA 02140, U.S.A. lmosyak@wyeth.com

Biochemical Society Transactions
|October 25, 2007
PubMed

Insights

Researchers are developing protein kinase Ctheta (PKCtheta) antagonists to treat diseases like asthma and autoimmune disorders. Small molecules blocking PKCtheta

Area of Science:

  • Immunology
  • Pharmacology
  • Structural Biology

Background:

  • Protein kinase Ctheta (PKCtheta) is a key signaling molecule in T-cell activation.
  • Dysregulation of PKCtheta is implicated in inflammatory and autoimmune diseases.
  • Current drug discovery efforts target PKC inhibitors for cancer, diabetes, and arthritis.

Purpose of the Study:

  • To develop novel PKCtheta antagonists for treating asthma and autoimmune diseases.
  • To identify small-molecule agents that inhibit PKCtheta's catalytic activity.

Main Methods:

  • Discovery of lead chemical series targeting PKCtheta.
  • Application of X-ray crystallography and computational modeling.
  • Utilization of a structure-surrogate strategy for lead optimization.

Main Results:

  • Identification of promising lead chemical series for PKCtheta antagonism.
  • Structural insights guided the optimization of lead compounds.
  • Demonstrated feasibility of a structure-surrogate approach in drug design.

Conclusions:

  • PKCtheta antagonists represent a viable therapeutic strategy for allergic and autoimmune conditions.
  • Integrated structural and chemical approaches accelerate the discovery of potent inhibitors.
  • The developed methodology facilitates the optimization of small-molecule drug candidates.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...